Metabolite

KNApSAcK Entry

id C00003520
Name Ginsenoside Rg1
CAS RN 22427-39-0
Standard InChI InChI=1S/C42H72O14/c1-20(2)10-9-13-42(8,56-37-34(52)32(50)30(48)25(19-44)55-37)21-11-15-40(6)28(21)22(45)16-26-39(5)14-12-27(46)38(3,4)35(39)23(17-41(26,40)7)53-36-33(51)31(49)29(47)24(18-43)54-36/h10,21-37,43-52H,9,11-19H2,1-8H3/t21-,22+,23-,24?,25?,26+,27-,28-,29+,30+,31?,32-,33?,34?,35-,36+,37-,39+,40+,41+,42-/m0/s1
Standard InChI (Main Layer) InChI=1S/C42H72O14/c1-20(2)10-9-13-42(8,56-37-34(52)32(50)30(48)25(19-44)55-37)21-11-15-40(6)28(21)22(45)16-26-39(5)14-12-27(46)38(3,4)35(39)23(17-41(26,40)7)53-36-33(51)31(49)29(47)24(18-43)54-36/h10,21-37,43-52H,9,11-19H2,1-8H3

Cluster

Phytochemical cluster No. 51
KCF-S cluster No. 32

Link

ChEMBL

By standard InChI
By standard InChI Main Layer CHEMBL501637 CHEMBL1977916

KEGG

By LinkDB C08946

CTD

By CAS RN C035054

Human Protein / Gene in interaction

CTD interaction (6)

compound gene gene name gene description interaction interaction type form reference
pmid
C035054 898 CCNE1
CCNE
cyclin E1 ginsenoside Rg1 affects the reaction [tert-Butylhydroperoxide affects the expression of CCNE1 protein] affects expression
/ affects reaction
protein 15606011
C035054 1017 CDK2
p33(CDK2)
cyclin-dependent kinase 2 (EC:2.7.11.22) ginsenoside Rg1 affects the reaction [tert-Butylhydroperoxide affects the expression of CDK2 protein] affects expression
/ affects reaction
protein 15606011
C035054 1026 CDKN1A
CAP20
CDKN1
CIP1
MDA-6
P21
SDI1
WAF1
p21CIP1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) ginsenoside Rg1 affects the reaction [tert-Butylhydroperoxide affects the expression of CDKN1A protein] affects expression
/ affects reaction
protein 15606011
C035054 3757 KCNH2
ERG1
HERG
HERG1
Kv11.1
LQT2
SQT1
potassium voltage-gated channel, subfamily H (eag-related), member 2 ginsenoside Rg1 affects the activity of KCNH2 protein affects activity
protein 15842772
C035054 4780 NFE2L2
NRF2
nuclear factor, erythroid 2-like 2 [ginsenoside Rg1 co-treated with ginsenoside 20S-protopanaxatriol] results in increased expression of NFE2L2 protein affects cotreatment
/ increases expression
protein 22780686
C035054 4780 NFE2L2
NRF2
nuclear factor, erythroid 2-like 2 ginsenoside Rg1 results in increased expression of NFE2L2 mRNA increases expression
mRNA 22780686

Related Disease

Diseases related to CTD interactions

6 disease from interactions of metabolites

MeSH disease OMIM compound disease name evidence type reference
pmid
D003704 C035054 Dementia therapeutic
20564503
D003928 C035054 Diabetic Nephropathies therapeutic
20481316
D006948 C035054 Hyperkinesis therapeutic
9559335
9643450
D007249 C035054 Inflammation therapeutic
22214447
D007859 C035054 Learning Disorders therapeutic
18308784
22484447
D008569 C035054 Memory Disorders therapeutic
22484447